Survival analysis.

Por CROWLEY, JOHN
Publicado em c198

Better Method for Occluding Umbilical Cord

Por Crowley, John
Publicado em 1965

Prognostic implications of cumulative dosing in total therapy 3

Por Barlogie, Bart, Crowley, John
Publicado em 2012

DNA cytometry testing for cervical cancer screening: approaches and reporting standards for new technologies

Por Colditz, Graham A, Crowley, John
Publicado em 2011

The Automatic Clinical Trial: Leveraging the Electronic Medical Record in Multi-site Cancer Clinical Trials

Por Goodman, Keith, Krueger, Judy, Crowley, John
Publicado em 2012

Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors

Por Korn, Ronald L., Crowley, John J.
Publicado em 2013

Response: Top tertile SFLC reduction indeed is an independent feature of myeloma aggressiveness

Por van Rhee, Frits, Crowley, John, Barlogie, Bart
Publicado em 2008

Seamless Phase I–II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents

Por Hoering, Antje, LeBlanc, Mike, Crowley, John
Publicado no Clin Cancer Res (2010)

Randomized Phase III ClinicalTrial Designs forTargeted Agents

Por Hoering, Antje, LeBlanc, Mike, Crowley, John J.
Publicado em 2008

Collapse of a hockey player: ruptured aneurysm of the renal artery

Por Smart, Gavin W., Crowley, John S., Lavoie, Denis J.
Publicado em 2010

Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival

Por Barlogie, Bart, Bolejack, Vanessa, Schell, Michael, Crowley, John
Publicado em 2010

Dynamics of fast and slow inhibition from cerebellar Golgi cells allow flexible control of synaptic integration

Por Crowley, John J., Fioravante, Diasynou, Regehr, Wade G.
Publicado em 2009

Randomization and Statistical Power: Paramount in Trial Reproducibility (Even for Rare Cancers)

Por Baker, Laurence H., Crowley, John J., Maki, Robert G.
Publicado em 2012

Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents

Por Hoering, Antje, Mitchell, Alan, LeBlanc, Michael, Crowley, John
Publicado em 2013

Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma

Por Burington, Bart, Barlogie, Bart, Zhan, Fenghuang, Crowley, John, Shaughnessy, John D.
Publicado em 2008

Cure Models as a Useful Statistical Tool for Analyzing Survival

Por Othus, Megan, Barlogie, Bart, LeBlanc, Michael L., Crowley, John J.
Publicado em 2012

Randomized Phase II Designs

Por Rubinstein, Larry, Crowley, John, Ivy, Percy, LeBlanc, Michael, Sargent, Dan
Publicado em 2009

The relationship between HLA‐DRB1 alleles and optic neuritis in Irish patients and the risk of developing multiple sclerosis

Por Tuwir, Ismail, Dunne, Ciaran, Crowley, John, Saddik, Tarik, Murphy, Ray, Cassidy, Lorraine
Publicado em 2007

Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols

Por Nair, Bijay, Waheed, Sarah, Szymonifka, Jackie, Shaughnessy, John D., Crowley, John, Barlogie, Bart
Publicado em 2008

Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine

Por Matsui, Shigeyuki, Simon, Richard, Qu, Pingping, Shaughnessy, John D., Barlogie, Bart, Crowley, John
Publicado em 2012